Are Diabetic Patients at Increased Risk for Biochemical Recurrence After Radical Prostatectomy?
biochemical recurrence
diabetes mellitus
outcome
prostate cancer
risk factor
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
04
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Introduction Diabetic patients are at a lower risk for prostate cancer. However, the relationship between diabetes mellitus (DM) and biochemical recurrence (BCR) after radical prostatectomy (RP) is less clear. The goal of our study was to determine diabetes's value as a biochemical recurrence predictor. Materials and methods We conducted a retrospective analysis of 117 patients who had undergone open radical prostatectomy between 1999 and 2021 at our institution. Univariate and multivariate statistical analyses were used to identify factors associated with biochemical recurrence. Results On univariate analysis, factors associated with biochemical recurrence were diabetes (p=0.002), preoperative prostate-specific antigen (PSA) levels (p=0.022), positive digital rectal exam (p=0.035), number of positive biopsy cores (p<0.001), unfavorable intermediate risk group (p=0.014), peri-neural invasion (PNI) on RP specimen (p=0.043), tumor volume (p=0.011), and positive surgical margins (p<0.001). Multivariate analysis showed that factors independently associated with biochemical recurrence were diabetes (p=0.039; OR=2.788), number of positive cores (p=0.016; OR=4.124), and positive surgical margins (p=0.008; OR=3.876). Conclusion A history of diabetes mellitus should be taken into consideration when assessing patients' risk of biochemical recurrence after radical prostatectomy. More research on a larger scale is needed to determine diabetes' value as a biochemical predictor.
Identifiants
pubmed: 35663714
doi: 10.7759/cureus.24717
pmc: PMC9164171
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e24717Informations de copyright
Copyright © 2022, Ben Hadj Alouane et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Urol. 2007 Sep;52(3):733-43
pubmed: 17350750
Cancer Causes Control. 2016 Jan;27(1):105-13
pubmed: 26537119
Sci Rep. 2018 Aug 10;8(1):11962
pubmed: 30097640
Cancer Causes Control. 2005 Sep;16(7):789-97
pubmed: 16132789
Prog Urol. 2018 Jun;28(8-9):442-449
pubmed: 29789237
World J Surg Oncol. 2018 Jul 3;16(1):124
pubmed: 29970100
Urology. 2010 Nov;76(5):1240-4
pubmed: 20627287
J Clin Oncol. 2007 May 1;25(13):1765-71
pubmed: 17470867
Lung Cancer. 2012 Mar;75(3):381-90
pubmed: 21864933
Ann Surg Oncol. 2008 Jul;15(7):1931-6
pubmed: 18418656
World J Urol. 2014 Aug;32(4):999-1005
pubmed: 24062093
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):151-8, S1
pubmed: 23032360
Prostate Cancer Prostatic Dis. 2014 Sep;17(3):233-7
pubmed: 24841331
Diabetes Metab Res Rev. 2015 May;31(4):336-43
pubmed: 25066306
Int Urol Nephrol. 2016 Sep;48(9):1437-43
pubmed: 27170341
J Clin Oncol. 2003 Feb 1;21(3):433-40
pubmed: 12560431
World J Surg Oncol. 2015 Nov 05;13:311
pubmed: 26542246
Eur Urol Focus. 2020 Mar 15;6(2):231-234
pubmed: 31248850
Cancer. 2019 Aug 15;125(16):2861-2867
pubmed: 31034601
Lancet. 2004 Apr 24;363(9418):1346-53
pubmed: 15110491
J Contemp Brachytherapy. 2014 Oct;6(3):254-61
pubmed: 25337126
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):9-17
pubmed: 20056618
Eur Urol. 2013 Apr;63(4):709-16
pubmed: 23287698
Sci Rep. 2021 Jun 7;11(1):12002
pubmed: 34099748
Med Oncol. 2006;23(3):341-6
pubmed: 17018891
Urol Oncol. 2014 Jan;32(1):43.e1-7
pubmed: 23810664
J Clin Endocrinol Metab. 2008 May;93(5):1834-40
pubmed: 18319314
Autophagy. 2010 Jul 1;6(5):670-671
pubmed: 28157435